Figure 3.

Meta-analyses of the MBL signature’s association with response and survival in three immune checkpoint inhibitor datasets. Z-score absolute values indicating significance of the association between A, MBL score and clinical benefit in response to immune checkpoint inhibitor therapy using the two-tailed Wilcoxon sum-rank test and B, MBL score and either progression-free (anti-PD-L1) or overall survival (anti-PD-1, anti-CTLA-4) using the log-rank test. Light gray line indicates a z-score equal to 1.96 (P < 0.05). Z-scores from the PD-1 and PD-L1 cohort were combined using Stouffer’s method to get the PD-1/PD-L1 meta-z-score. Z-scores from all three datasets were combined using Stouffer’s method to get the meta-z-score. All p-values correspond to their respective z-scores.